Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity remains negative

Q1 FY2026 total equity was -$37.31M, compared with -$55.07M a year earlier.

Context

  • Total equity amounted to 186.6% of total assets at the end of Q1 FY2026, up 97.8 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +32.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$37.31M+3.1% QoQ
Last fiscal yearDec 2025
-$38.5M+60.4% YoY
Year agoMar 2025
-$55.07M+32.2% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.2%——
1 year+60.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(38.5M) USD
Year-over-year change
+60.4%

Total Equity vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +32.2% is the 5th highest of 11, against a peer median of -31.3%.
  • Total equity amounts to 186.6% of total assets for ATRA, versus a peer median of 87.3%.
ATRA Competitors
Total Equity for ATRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORMPOramed Pharmaceuticals Inc.Mar 2026$238.28M USD+70.3%+9.7%88.6%
OVIDOvid Therapeutics Inc.Mar 2026$198.27M USD+234.5%-0.4%87.9%
STTKShattuck Labs, Inc.Mar 2026$95.84M USD+41.8%-22.4%93.8%
CNTXContext Therapeutics Inc.Mar 2026$52.2M USD-42.6%+20.3%88.7%
COYACoya Therapeutics, Inc.Mar 2026$48.97M USD+46.8%—91.9%
IFRXInflaRx N.V.Mar 2026€36.93M EUR-47.6%-22.2%75.5%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
CSBRChampions Oncology, Inc.Jan 2026$4.38M USD-19.9%-25.4%15.4%
CLNNClene Inc.Mar 2026-$18.81M USD-278.2%—86.8%
ATRAAtara Biotherapeutics, Inc.Mar 2026-$37.31M USD+32.2%—186.6%
STROSutro Biopharma, Inc.Mar 2026-$66.89M USD-159.1%—27.6%
Peer median (excluding ATRA) —-31.3%-22.2%87.3%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents106.08M92.94M25.84M25.03M8.48M
Short-term Investments264.98M149.88M25.88M17.47M0
Net Receivables986K40.22M34.11M1.48M1.25M
Inventory01.59M9.71M10.66M0
Other Current Assets194K10.45M6.33M10.26M2.48M
Total Current Assets384.62M295.08M101.87M64.89M12.21M
Property, Plant & Equipment (Net)79.94M74.32M58.79M41.1M7.14M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets3.57M7.02M4.84M3.1M886K
Total Non-current Assets83.51M81.34M63.64M44.2M8.02M
Total Assets468.13M376.42M165.5M109.1M20.24M
Account Payables17.37M6.87M3.68M4.37M127K
Short-term Debt000010.78M
Tax Payables00000
Deferred Revenue40.76M8M77.83M95.09M716K
Other Current Liabilities25.15M32.75M37.01M6.59M2.03M
Total Current Liabilities105.79M78.92M142.23M134.57M14.92M
Long-term Debt000032.67M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)55.71M77M37.56M00
Other Non-current Liabilities1.5M35.8M39.25M41.89M1.8M
Total Non-current Liabilities82.73M170.86M122.51M71.81M43.82M
Total Liabilities188.51M249.78M264.74M206.38M58.74M
Common Stock9K10K11K1K1K
Retained Earnings(1.46B)(1.69B)(1.97B)(2.05B)(2.02B)
Accumulated OCI(368K)(2.07M)(204K)8K1K
Other Stockholders Equity00000
Minority Interest00000
Total Equity279.61M126.64M(99.23M)(97.28M)(38.5M)
Total Debt28.27M71.7M57.87M43.83M52.8M
Net Debt(77.81M)(21.24M)32.03M18.8M44.32M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.